美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

219.95

-4.7800-2.13%

盤前：222.993.04+1.38%08:55 EDT

成交量：26.28萬

成交額：5,823.34萬

市值：237.67億

市盈率：-59.39

高：225.91

開：223.20

低：218.31

收：224.73

資料載入中...

總覽公司新聞公告

百濟神州勝訴

百濟神州5月2日成交額為4631.11萬美元

港股醫藥股走勢疲軟，百濟神州跌近6%

每日经济新闻

兩大千億營收巨頭領跑！雲南白藥首破400億，百濟神州、恆瑞大漲，人福、片仔癀……創新高

百濟神州因受限制股份單位獲歸屬發行28.8萬股

百濟神州(06160)因受限制股份單位獲歸屬發行28.8萬股

百濟神州BCL-2抑制劑申報上市

百濟神州4月30日成交額為9176.79萬美元

跨國藥企碰瓷失敗，百濟神州專利保衞戰大捷

百濟神州參投，可編程 mRNA實現 IL-12瘤內定向激活，開啓“mRNA 2.0”

美股異動 | 百濟神州(ONC.US)漲逾3% 2024年收入同比增長55%

百濟神州在美國專利糾紛中獲勝，USPTO裁定相關專利無效

百濟神州在美贏得專利訴訟，艾伯維Pharmacyclics公司專利判無效

百濟神州：Pharmacyclics訴訟所涉專利被裁定無效

創新藥產業鏈表現良好，百濟神州、諾誠健華、恆瑞醫藥等持續活躍

百濟神州“澤布替尼”專利侵權案勝訴

医药魔方Info

回港中概股午後走強，金山雲漲超13%，百濟神州漲超7%，萬國數據漲超6%，寶尊電商、BOSS直聘漲超2%。

回港中概股午後走強，金山雲(03896.HK)漲超13%，百濟神州(06160.HK)漲超7%，萬國數據(09698.H

A股創新藥概念持續走強，百濟神州、諾誠健華、錦波生物均創出歷史新高，科倫藥業、益方生物、澤璟製藥、華東醫藥、恆瑞醫藥等漲

百濟神州：盤中漲超 5% 24 年收入增 55%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":219.95,"timestamp":1747252800000,"preClose":224.73,"halted":0,"volume":262785,"hourTrading":{"tag":"盘前","latestPrice":222.99,"preClose":219.95,"latestTime":"08:55 EDT","volume":58,"amount":12914.24926,"timestamp":1747313736340},"delay":0,"floatShares":69370116,"shares":108055817,"eps":-3.70325,"marketStatus":"盤前交易","change":-4.78,"latestTime":"05-15 09:03:42 EDT","open":223.2,"high":225.91,"low":218.31,"amount":58233410.90145,"amplitude":0.033818,"askPrice":227,"askSize":8,"bidPrice":210,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747315800000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":219.95,"preHourTrading":{"tag":"盘前","latestPrice":222.99,"preClose":219.95,"latestTime":"08:55 EDT","volume":58,"amount":12914.24926,"timestamp":1747313736340},"postHourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"volumeRatio":0.5238388349596275,"impliedVol":0.404,"impliedVolPercentile":0.1868},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":69370116,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.5238388349596275,"shares":108055817,"dividePrice":0,"high":225.91,"amplitude":0.033818,"preClose":224.73,"low":218.31,"week52Low":141.31,"pbRate":"6.79","psRate":"5.69","week52High":287.88,"institutionHeld":0,"latestPrice":219.95,"committee":-0.6,"eps":-3.70325,"divideRate":0,"volume":262785,"delay":0,"ttmEps":-3.70325,"open":223.2,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":232.25,"twentyDayClose":238.84,"sixtyDayClose":238.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532360144","title":"百濟神州勝訴","url":"https://stock-news.laohu8.com/highlight/detail?id=2532360144","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532360144?lang=zh_tw&edition=fundamental","pubTime":"2025-05-04 10:01","pubTimestamp":1746324060,"startTime":"0","endTime":"0","summary":"百济神州宣布胜诉，USPTO裁定Pharmacyclics的‘803专利无效，该专利是艾伯维子公司对百济神州产品百悦泽®提出的侵权指控的核心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0},{"id":"2532802797","title":"百濟神州5月2日成交額為4631.11萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532802797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532802797?lang=zh_tw&edition=fundamental","pubTime":"2025-05-03 10:17","pubTimestamp":1746238671,"startTime":"0","endTime":"0","summary":"美东时间2025年5月2日，百济神州成交额为4631.11万美元，成交额较昨日减少45.66%，当日成交量为18.04万股。百济神州于2025年5月2日涨0.05%，报255.77美元，该股过去5个交易日涨4.44%，年初至今涨38.47%，过去60日涨12.34%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503101758a6d1a075&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503101758a6d1a075&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2532185122","title":"港股醫藥股走勢疲軟，百濟神州跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532185122","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532185122?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 09:55","pubTimestamp":1746150915,"startTime":"0","endTime":"0","summary":"港股医药股走势疲软，百济神州跌近6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505023395436693.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505023395436693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","ONC","BK1583","LU2328871848.SGD","06160","BK1161","BK4139","BK1588","LU0307460666.USD","BK1500","LU1969619763.USD"],"gpt_icon":0},{"id":"2532633888","title":"兩大千億營收巨頭領跑！雲南白藥首破400億，百濟神州、恆瑞大漲，人福、片仔癀……創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2532633888","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532633888?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 08:09","pubTimestamp":1746144552,"startTime":"0","endTime":"0","summary":"从营收增速来看，百济神州、新和成、恒瑞医药、华润三九等5家均有双位数增长；智飞生物跌幅最大，超过50%。上海医药、九州通两家千亿营收龙头继续领跑，重药控股、南京医药、国药股份均超过500亿元。创新高，云南白药首破400亿此外，人福医药、恒瑞医药、科伦药业、片仔癀等超20家创新高。其中，国药股份首次突破500亿元，云南白药首次突破400亿元，百济神州、新和成和鹭燕医药首次突破200亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502114021a46f932b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502114021a46f932b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600436","688235","000538","ONC","600276","06160"],"gpt_icon":0},{"id":"2532071837","title":"百濟神州因受限制股份單位獲歸屬發行28.8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532071837","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532071837?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 07:59","pubTimestamp":1746143940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，于2025年4月30日，因根据股权计划授出的受限制股份单位获归属（公司董事除外）而发行28.8万股。\n　　于2025年4月30日，因合资格参与者（公司董事除外）行使购股权而发行合计113.1万股。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-02/doc-inevcpfk0018566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0307460666.USD","LU2328871848.SGD","06160","ONC","BK1161","LU1969619763.USD","BK4139","BK0239","BK1588","LU0588546209.SGD","BK1583","BK1500","688235"],"gpt_icon":0},{"id":"2532377318","title":"百濟神州(06160)因受限制股份單位獲歸屬發行28.8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532377318","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532377318?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 07:49","pubTimestamp":1746143373,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年4月30日，因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行28.8万股。于2025年4月30日，因合资格参与者(公司董事除外)行使购股权而发行合计113.1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK0239","LU0307460666.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1588","BK1500","688235","BK4139","BK1583","ONC","BK1161"],"gpt_icon":0},{"id":"2532886091","title":"百濟神州BCL-2抑制劑申報上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2532886091","media":"医药地理","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532886091?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 17:22","pubTimestamp":1746091342,"startTime":"0","endTime":"0","summary":"4月28日，国家药品监督管理局药品审评中心网站显示，百济神州的索托克拉片申报上市。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。根据百济神州介绍，与维奈克拉相比，索托克拉在临床前研究和肿瘤模型中均显示出更高的效力和靶点选择性，并有可能克服耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502013623a6d04148&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502013623a6d04148&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2532487660","title":"百濟神州4月30日成交額為9176.79萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532487660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532487660?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 10:18","pubTimestamp":1746065913,"startTime":"0","endTime":"0","summary":"美东时间2025年4月30日，百济神州成交额为9176.79万美元，成交额较昨日增加14.81%，当日成交量为35.31万股。百济神州于2025年4月30日涨4.02%，报259.81美元，该股过去5个交易日涨4.29%，年初至今涨40.66%，过去60日涨16.31%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501101837a6cf90a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501101837a6cf90a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2532704819","title":"跨國藥企碰瓷失敗，百濟神州專利保衞戰大捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2532704819","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532704819?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 07:30","pubTimestamp":1746055845,"startTime":"0","endTime":"0","summary":"2025年4月29日，美国专利商标局作出了一项最终书面决定，宣布艾伯维旗下的Pharmacyclics公司在803专利授权后复审程序中受到质疑的803专利的全部权利无效。在2023年6月13日，Pharmacyclics公司作为申诉方，在美国特拉华州地方法院，对百济神州及其全资子公司BeOne Medicines USA提出申诉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104311a6cf956b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104311a6cf956b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK0239","06160"],"gpt_icon":0},{"id":"2532101739","title":"百濟神州參投，可編程 mRNA實現 IL-12瘤內定向激活，開啓“mRNA 2.0”","url":"https://stock-news.laohu8.com/highlight/detail?id=2532101739","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532101739?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 07:21","pubTimestamp":1746055260,"startTime":"0","endTime":"0","summary":"Strand Therapeutics展示了一种可编程mRNA疗法STX-003，能精准调控IL-12在肿瘤组织的表达，提高耐受性并维持抗肿瘤疗效，其核心优势在于自复制mRNA与遗传电路的结合，为肿瘤治疗提供创新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","688235","BK1500","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","ONC","BK1161","06160","BK1588","BK1583"],"gpt_icon":0},{"id":"2531205560","title":"美股異動 | 百濟神州(ONC.US)漲逾3% 2024年收入同比增長55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531205560","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531205560?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 21:59","pubTimestamp":1746021564,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报259美元。财报显示，百济神州2024年实现收入合计约38.1亿美元，同比增长约55%；产品收入同比增长约72.6%至约38亿美元。4月30日早间，百济神州公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics在‘803 专利授权后复审程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提起上诉。公司表示，百悦泽是其原研药品，公司将对此类专利侵权指控进行坚决的辩护。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","688235","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","ONC","BK1161","BK1588","BK1500","BK1583","LU0588546209.SGD","BK0239","06160"],"gpt_icon":0},{"id":"2531031201","title":"百濟神州在美國專利糾紛中獲勝，USPTO裁定相關專利無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031201","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031201?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 20:10","pubTimestamp":1746015004,"startTime":"0","endTime":"0","summary":"4月30日，百济神州公告表示，美国专利商标局近日作出决定，宣告Pharmacyclics公司持有的第11672803号美国专利全部权利要求无效。这一裁定源于百济神州及其美国子公司与Pharmacyclics之间的一场专利纠纷。面对指控，百济神州迅速作出反应，于2023年11月向USPTO提交专利授权后复审申请，对“803专利”的合法性提出质疑。同时，法院也暂缓了侵权诉讼的审理，以待USPTO的裁决结果。基于以上理由，USPTO最终裁定“803专利”全部权利要求无效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK0239","ONC"],"gpt_icon":0},{"id":"2531087307","title":"百濟神州在美贏得專利訴訟，艾伯維Pharmacyclics公司專利判無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531087307","media":"财经涂鸦","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531087307?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 14:52","pubTimestamp":1745995963,"startTime":"0","endTime":"0","summary":"“诉讼目前未对百悦泽在美国的研发和销售产生不利影响。”此前，2023年6月13日，Pharmacyclics向美国特拉华州地方法院提起诉讼，指控百济神州及其全资子公司相关活动导致百悦泽对其“803专利”造成侵权。而泽布替尼与艾伯维/Pharmacyclics重磅药物依布替尼同属BTK抑制剂系列，两款产品有直接竞争关系。Pharmacyclics可对USPTO的最终书面决定提起上诉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043015171594e89cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043015171594e89cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","ABBV","BK0239","688235"],"gpt_icon":0},{"id":"2531056717","title":"百濟神州：Pharmacyclics訴訟所涉專利被裁定無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531056717","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531056717?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 14:16","pubTimestamp":1745993763,"startTime":"0","endTime":"0","summary":"中新经纬4月30日电 30日早间，百济神州发布一则涉及诉讼的公告。该诉讼起源于2023年6月，美国生物制药公司艾伯维旗下的Pharmacyclics公司指控百济神州的药物泽布替尼侵犯专利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","ONC","06160","688235"],"gpt_icon":0},{"id":"2531722937","title":"創新藥產業鏈表現良好，百濟神州、諾誠健華、恆瑞醫藥等持續活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722937","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531722937?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 14:14","pubTimestamp":1745993640,"startTime":"0","endTime":"0","summary":"创新药产业链表现强劲，多家企业如百济神州、诺诚健华和恒瑞医药等持续活跃。百济神州2024年营收同比增长56.19%，核心产品泽布替尼和替雷利珠单抗收入显著增长，预计2025年实现全年经营利润为正。诺诚健华的BCL2抑制剂ICP-248片拟纳入突破性治疗品种，奥布替尼新适应症获批用于一线治疗CLL/SLL。锦波生物2024年营收同比增长84.92%。机构看好创新药产业链在2024年的持续良好表现，认为医药行业将迎来结构性机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK0196","600276","BK0188","159992","LU2328871848.SGD","ONC","BK0060","688428","LU1064131003.USD","BK0239","LU2488822045.USD","09969","BK0012","06160","LU2148510915.USD","BK0028","LU0405327148.USD","LU1328615791.USD","LU1064130708.USD","688235","BK0183","LU0405327494.USD"],"gpt_icon":0},{"id":"2531708753","title":"百濟神州“澤布替尼”專利侵權案勝訴","url":"https://stock-news.laohu8.com/highlight/detail?id=2531708753","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531708753?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 13:59","pubTimestamp":1745992799,"startTime":"0","endTime":"0","summary":"4月30日，百济神州宣布，美国专利商标局（USPTO）作出了一项最终书面决定，宣布艾伯维旗下Pharmacyclics LLC在专利授权后复审（PGR）程序中受到百济神州质疑的第11672803号美国专利（‘803专利）的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提出上诉。该诉讼经过如下：2023年6月15日，Pharmacyclics指控百济神州BTK抑制剂百悦泽（泽布","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0},{"id":"2531377644","title":"回港中概股午後走強，金山雲漲超13%，百濟神州漲超7%，萬國數據漲超6%，寶尊電商、BOSS直聘漲超2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531377644","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531377644?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 13:36","pubTimestamp":1745991360,"startTime":"0","endTime":"0","summary":"回港中概股午后走强，金山云涨超13%，百济神州涨超7%，万国数据涨超6%，宝尊电商、BOSS直聘涨超2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30133650037219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06160","BK1586","BK1613","BK4531","BK4614","BK4505","BK4502","BK1588","BK4607","BK1517","BZ","03888","09698","TTTN","688235","ONC","LU0307460666.USD","BK1589","BK1607","LU1023057109.AUD","BK4509","LU0359201612.USD","BK4122","BK1518","LU2039709279.SGD","BK1500","BK1583","LU0348766576.USD","BK4585","BK4077","LU1688375341.USD","BK4220","BK4551","LU0359202008.SGD","BK0239","BK4563","BK4503","GDS","BK4608","BK1585","LU0588546209.SGD","LU0348767384.USD","LU1969619763.USD","BK1526","BZUN","BK1575","BK4588","BK1134"],"gpt_icon":0},{"id":"2531754057","title":"回港中概股午後走強，金山雲(03896.HK)漲超13%，百濟神州(06160.HK)漲超7%，萬國數據(09698.H","url":"https://stock-news.laohu8.com/highlight/detail?id=2531754057","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531754057?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 13:33","pubTimestamp":1745991202,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"02ef7766aaeb258258a594519db630be","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["02076","BK4502","BK4563","LU1023057109.AUD","03888","BK4509","BK1249","BK1501","BK1531","BK1588","BK4551","BK1500","BK4558","BK4614","BK1142","BK0239","BK4077","BK4505","688235","BK1518","BK1585","BK4529","BK1607","BK1526","LU2328871848.SGD","BZ","BK4503","BK1502","KC","BK4122","BK4608","BK1517","03896","BK1589","BK4526","BK4607","06160","09698","TTTN","LU0359201612.USD","GDS","09991","BK4220","LU2039709279.SGD","BK1583","LU0348767384.USD","ONC","BK4535","BZUN","BK1586"],"gpt_icon":0},{"id":"2531735757","title":"A股創新藥概念持續走強，百濟神州、諾誠健華、錦波生物均創出歷史新高，科倫藥業、益方生物、澤璟製藥、華東醫藥、恆瑞醫藥等漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531735757?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","688382","BK1588","159982","BK0175","002422","688235","BK1583","000963","BK4139","LU0405327148.USD","600276","BK0188","LU1328615791.USD","LU0588546209.SGD","LU2148510915.USD","06160","159992","BK0028","09969","BK0209","BK0060","LU1969619763.USD","BK1161","BK0012","BK0183","BK0187","BK1500","BK0196","LU1064130708.USD","399300","LU1064131003.USD","LU2328871848.SGD","BK0132","BK0239","BK1574","LU0307460666.USD","688266","LU2488822045.USD","688428","LU0405327494.USD","ONC"],"gpt_icon":0},{"id":"2531771649","title":"百濟神州：盤中漲超 5% 24 年收入增 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531771649","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531771649?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 12:42","pubTimestamp":1745988165,"startTime":"0","endTime":"0","summary":"百济神州盘中涨超 6%，截至发稿，股价上涨 5.50%，现报 157.20 港元，成交额 5.72 亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135427974b21a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135427974b21a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-14","current":-61.889623,"percent":0.044944,"low":-64.911375,"twenty":-43.424174,"median":-39.182934,"eighty":-28.820246,"high":-22.805663,"avg":-37.41726,"sd":9.466346,"marketCap":24283383754},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-14","current":-61.889623,"twenty":-43.424174,"median":-39.182934,"eighty":-28.820246,"marketCap":24283383754}],"updateTime":1747314222968}}}